In conclusion, our results show that the human microbiome can produce physiological stimuli that can alter the drug delivery capacity of lipidic carriers. These results suggest that the presence of the human microbiome and its interaction with lipidic nanomaterials should be taken into consideration in the designing of drug formulation, or therapeutic agents. This aspect will be particularly important for the successful creation of lipidic carriers for the treatment of bacterial infections where bacterial concentrations can be much higher than in normal physiological fluids. Moreover, the intrinsic differences in microbiome population from body region to body region, and from patient to patient can be exploited to tune selectivity in drug release or towards the development of personalised medicine received the support of a fellowship from "la Caixa" Foundation (ID 100010434) and from the European Union's Horizon research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 847648. The fellowship code is LCF/BQ/PI20/11760019.